+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hypoglycemia - Pipeline Review, H1 2019

  • ID: 4767154
  • Drug Pipelines
  • 83 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Adocia SAS
  • Arecor Ltd
  • Novartis AG
  • Sosei Heptares
  • USV Pvt Ltd
  • Zealand Pharma AS
  • MORE
Hypoglycemia - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H1 2019, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights

This latest pipeline guide Hypoglycemia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 2, 5, 4 and 2 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adocia SAS
  • Arecor Ltd
  • Novartis AG
  • Sosei Heptares
  • USV Pvt Ltd
  • Zealand Pharma AS
  • MORE
Introduction

Report Coverage

Hypoglycemia - Overview

Hypoglycemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoglycemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoglycemia - Companies Involved in Therapeutics Development

Adocia SAS

AMAG Pharmaceuticals Inc

Arecor Ltd

Eiger BioPharmaceuticals Inc

Eli Lilly and Co

LATITUDE Pharmaceuticals Inc

Novartis AG

Rezolute Inc

Sosei Heptares

Therakind Ltd

USV Pvt Ltd

XERIS Pharmaceuticals Inc

Zealand Pharma AS

Zucara Therapeutics Inc

Hypoglycemia - Drug Profiles

avexitide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasiglucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glucagon biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3143753 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3185643 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-900018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RZ-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoglycemia - Dormant Projects

Hypoglycemia - Discontinued Products

Hypoglycemia - Product Development Milestones

Featured News & Press Releases

Mar 25, 2019: Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019

Mar 25, 2019: Xeris Pharmaceuticals presents new clinical and economic impact data on its developmental ready-to-use Glucagon

Mar 14, 2019: Xeris Pharmaceuticals doses first patient in phase 2 trial evaluating its ready-to-use glucagon to address exercise-induced hypoglycemia

Mar 07, 2019: Zealand Pharma begins dosing in Phase III trial for CHI

Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute

Feb 12, 2019: Adocia to present new clinical data on BioChaperone Glucagon at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)

Feb 04, 2019: Eiger BioPharmaceuticals announces oral presentation of phase 2 PREVENT study of avexitide in post-bariatric hypoglycemia (PBH) at upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

Jan 17, 2019: LATITUDE Pharmaceuticals receives notice of allowance for U.S. Patent Covering Stabilized Aqueous Glucagon Formulations

Dec 20, 2018: European medicines agency grants orphan drug designation for Xeris’ investigational ready to use glucagon for the treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)

Dec 11, 2018: Eiger BioPharmaceuticals provides update on Avexitide at 2018 R&D Day

Nov 12, 2018: Xeris Pharmaceuticals releases additional phase 3 clinical trial data on its ready-to-use Liquid Glucagon Pen

Oct 23, 2018: Xeris Pharmaceuticals announces FDA acceptance for review of NDA for its ready-to-use Glucagon Rescue Pen

Oct 16, 2018: Eiger BioPharmaceuticals announces positive results in phase 2 PREVENT study of Avexitide targeting GLP-1 in post-bariatric hypoglycemia (PBH)

Sep 27, 2018: Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children

Sep 18, 2018: Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hypoglycemia, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Hypoglycemia - Pipeline by Adocia SAS, H1 2019

Hypoglycemia - Pipeline by AMAG Pharmaceuticals Inc, H1 2019

Hypoglycemia - Pipeline by Arecor Ltd, H1 2019

Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H1 2019

Hypoglycemia - Pipeline by Eli Lilly and Co, H1 2019

Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2019

Hypoglycemia - Pipeline by Novartis AG, H1 2019

Hypoglycemia - Pipeline by Rezolute Inc, H1 2019

Hypoglycemia - Pipeline by Sosei Heptares, H1 2019

Hypoglycemia - Pipeline by Therakind Ltd, H1 2019

Hypoglycemia - Pipeline by USV Pvt Ltd, H1 2019

Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H1 2019

Hypoglycemia - Pipeline by Zealand Pharma AS, H1 2019

Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H1 2019

Hypoglycemia - Dormant Projects, H1 2019

Hypoglycemia - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Hypoglycemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adocia SAS
  • AMAG Pharmaceuticals Inc
  • Arecor Ltd
  • Eiger BioPharmaceuticals Inc
  • Eli Lilly and Co
  • LATITUDE Pharmaceuticals Inc
  • Novartis AG
  • Rezolute Inc
  • Sosei Heptares
  • Therakind Ltd
  • USV Pvt Ltd
  • XERIS Pharmaceuticals Inc
  • Zealand Pharma AS
  • Zucara Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4767154
Adroll
adroll